Acetaminophen products do not need aspirin cross-reactivity warning, McNeil argues.
This article was originally published in The Tan Sheet
Executive Summary
ASPIRIN-SENSITIVE WARNING ON ACETAMINOPHEN UNJUSTIFIED, McNEIL ARGUES in a May 15 response to a Whitehall-Robins Health- care submission to FDA proposing an aspirin cross-reactivity label warning be required on acetaminophen products. The marketer of Tylenol acetaminophen argues that after a review of the scientific data and evidence from the product's four-decade marketing history, "there is no substantial or credible scientific evidence that cross-reactivity between aspirin and acetaminophen occurs at any clinically important level." The firm concludes "there is no justification for an aspirin-sensitive cross-reactivity warning on acetaminophen products."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning